Jonathan Terdiman, MD


Dr. Jonathan Terdiman is co-director of the Center for Inflammatory Bowel Disease and the Colorectal Cancer Prevention Program at UCSF Medical Center. His research interests include colorectal cancer prevention, hereditary gastrointestinal cancer and inflammatory bowel disease. He frequently lectures in the community, at the university and for various professional organizations on these subjects.

Terdiman earned a medical degree at Columbia University, College of Physicians and Surgeons. He went on to complete a residency in internal medicine and fellowships in critical care medicine and gastroenterology at UCSF, where he is a professor of clinical medicine and surgery.


Colitis and Crohn's Disease Center
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 353-7921
Fax: (415) 502-2249

Gastroenterology at Mount Zion
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Conditions & Treatments

Board Certification

Gastroenterology, American Board of Internal Medicine

Academic Title


More about Jonathan Terdiman


Columbia University School of Medicine 1989


UCSF Medical Center, Internal Medicine 1992


UCSF Medical Center, Gastroenterology 1996

Selected Research and Publications

  1. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 Mar 10.
  2. Azofra AS, Kidambi TD, Jeremy RJ, Conrad P, Blanco A, Myers M, Barkovich J, Terdiman JP. Differences in neuropsychological and behavioral parameters and brain structure in patients with familial adenomatous polyposis: a sibling-paired study. Hered Cancer Clin Pract. 2016; 14:20.
  3. Kidambi TD, Lee R, Terdiman JP, Day L. Successful implementation of Lynch syndrome screening in a safety net institution. J Community Genet. 2016 Jul; 7(3):255-60.
  4. Kidambi TD, Blanco A, Van Ziffle J, Terdiman JP. Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome. Fam Cancer. 2016 Apr; 15(2):275-80.
  5. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
  6. Ho CK, Boscardin CK, Gleason N, Collado D, Terdiman J, Terrault NA, Gonzales R. Optimizing the pre-referral workup for gastroenterology and hepatology specialty care: consensus using the Delphi method. J Eval Clin Pract. 2016 Feb; 22(1):46-52.
  7. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan; 18(1):13-9.
  8. Kidambi TD, Terdiman JP. Screening for Lynch syndrome: it is time to shift the focus. Dig Dis Sci. 2015 Feb; 60(2):586-7.
  9. Lee JK, Terdiman JP, Corley DA. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Jul 10; 371(2):186.
  10. Kidambi TD, Blanco A, Myers M, Conrad P, Loranger K, Terdiman JP. Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci. 2015 Aug; 60(8):2463-9.
  11. Walsh JM, Potter MB, Arora M, Gildegorin G, Terdiman J. A workplace colorectal cancer screening program in firefighters: lessons learned. Occup Med (Lond). 2014 Jun; 64(4):255-8.
  12. Shah S, Terdiman J, Gundling K, Mahadevan U. Immunoglobulin therapy for refractory Crohn's disease. Therap Adv Gastroenterol. 2014 Mar; 7(2):99-102.
  13. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1459-63.
  14. Truta B, Li DX, Mahadevan U, Fisher ER, Chen YY, Grace K, Velayos F, Terdiman JP. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.
  15. Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012 Dec; 127(3):544-51.
  16. Kuppermann M, Wang G, Wong S, Blanco A, Conrad P, Nakagawa S, Terdiman J, Ladabaum U. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer. 2013 Jan 01; 119(1):215-25.
  17. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012 Nov; 18(11):2026-33.
  18. Larsen M, Hills N, Terdiman J. The impact of the quality of colon preparation on follow-up colonoscopy recommendations. Am J Gastroenterol. 2011 Dec; 106(12):2058-62.
  19. Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1013-9.
  20. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011 Jul 19; 155(2):69-79.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.